BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | 0.00 | -0.14 | -0.01 |
| FCF Yield | -30.12% | -24.29% | -78.82% | -32.29% |
| EV / EBITDA | -3.27 | -3.65 | 33.88 | -4.17 |
| Quality | ||||
| ROIC | -4.04% | -47.51% | -30.59% | -91.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.25 | 0.61 | 16.28 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 67.48% | 68.33% | 6.88% | -4.40% |
| Safety | ||||
| Net Debt / EBITDA | -0.71 | -0.48 | 5.17 | -0.77 |
| Interest Coverage | 0.00 | -3.22 | 0.21 | -5.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |